SCHEMBL2200068

SCHEMBL2200068

COc1ccc(C2CNC(=O)N2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
TP53 P04637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.45
NOS1 P29475 2/20 0.43
MAP2K1 Q02750 1/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
NOS3 P29474 1/20 0.43
TNKS2 Q9H2K2 2/20 0.42
MAOA P21397 3/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
PTGS2 P35354 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
MMP1 P03956 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410461 0.80 ALDH1A1 (0.61) ALDH1A1GAACRBNMAOANPC1
SCHEMBL12696878 0.78 DDB1 (0.40) KDM4ETP53ALDH1A1GAANOS1
SCHEMBL6827562 0.77 DDB1 (0.51) KDM4ETP53ALDH1A1GAAMAP2K1
SCHEMBL27761702 0.77 NOTUM (0.37) GAANOS1NPC1MAPTRAB9A
SCHEMBL19587006 0.77 ALDH1A1 (0.40) KDM4EALDH1A1GAAHPGDNPC1
SCHEMBL27898379 0.77 CYP19A1 (0.41) NOS1DDB1CRBNNOS3MAPT
SCHEMBL31324258 0.77 ESR2 (0.44) KDM4EALDH1A1NOS1
SCHEMBL3657517 0.76 CRBN (0.58) KDM4ETP53ALDH1A1GAAMAP2K1
SCHEMBL10041515 0.76 NOS1 (0.49) KDM4EALDH1A1GAANOS1HPGD
SCHEMBL2199447 0.76 NOS1 (0.49) KDM4EALDH1A1GAANOS1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977334-B2 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-12 US disclosed
US-20080234278-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions TRIESELMANN THOMAS 2008-09-25 US disclosed
EP-1781620-A1 NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-09 EP disclosed
WO-2005108373-A1 NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-17 WO disclosed
US-20050245526-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234278-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 KDM4E 4431/4885TP53 4121/4885ALDH1A1 674/4885
US-20050245526-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 KDM4E 4431/4885TP53 4121/4885ALDH1A1 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.